Showing results (1951-1960 of 2,232) with videos related to

Sort By:
Pageof 224
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 28, 2024
Deciphering the Multifaceted Immune Landscape of Unresectable Primary Liver Cancer to Predict Immunotherapy ResponseJun Xue, Shuai Yang, Si-Si Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2020
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung CancerSachiko Arai, Shinji Takeuchi, Koji Fukuda, et al.
Thoracic Cancer|September 7, 2020
Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1+ CD8+ and CD8+ T cells as predictive of response to neoadjuvant chemotherapy in breast cancerHongling Liang, Hongsheng Li, Zhi Xie, et al.
World Neurosurgery|March 8, 2021
Different Types of Double-Level Degenerative Lumber Spondylolisthesis: What Is Different in the Sagittal Plane?Guang-Zhi Zhang, Ya-Jun Deng, Xue-Gang He, et al.
JCI Insight|April 24, 2023
FRC transplantation restores lymph node conduit defects in laminin α4-deficient miceLushen Li, Long Wu, Allison Kensiski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung CancerYi-Long Wu, Shun Lu, You Lu, et al.
World Journal of Surgical Oncology|January 11, 2017
Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective studySong Dong, Ning Zhao, Wei Deng, et al.
Signal Transduction and Targeted Therapy|May 14, 2023
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancerJi Zhou, Xu-Chao Zhang, Shan Xue, et al.
JTO Clinical and Research Reports|February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup AnalysisJie Wang, Yi-Long Wu, Shun Lu, et al.
The Lancet. Respiratory Medicine|July 24, 2017
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trialJin-Ji Yang, Caicun Zhou, Yisheng Huang, et al.
Pageof 224